Goldman Sachs’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.11M | Buy |
475,922
+224,577
| +89% | +$476K | ﹤0.01% | 5131 |
|
|
2026
Q1 | $545K | Sell |
251,345
-11,464
| -4% | -$28.4K | ﹤0.01% | 5549 |
|
|
2025
Q4 | $473K | Buy |
262,809
+111,980
| +74% | +$229K | ﹤0.01% | 5629 |
|
|
2025
Q3 | $335K | Buy |
150,829
+48,651
| +48% | +$79.2K | ﹤0.01% | 5701 |
|
|
2025
Q2 | $151K | Sell |
102,178
-187,283
| -65% | -$383K | ﹤0.01% | 5736 |
|
|
2025
Q1 | $741K | Buy |
289,461
+239,751
| +482% | +$573K | ﹤0.01% | 4923 |
|
|
2024
Q4 | $93.5K | Sell |
49,710
-531
| -1% | -$751 | ﹤0.01% | 5775 |
|
|
2024
Q3 | $51.2K | Sell |
50,241
-411,717
| -89% | -$433K | ﹤0.01% | 5630 |
|
|
2024
Q2 | $540K | Buy |
461,958
+369,534
| +400% | +$437K | ﹤0.01% | 4787 |
|
|
2024
Q1 | $116K | Sell |
92,424
-12,052
| -12% | -$18K | ﹤0.01% | 5219 |
|
|
2023
Q4 | $186K | Sell |
104,476
-3,319
| -3% | -$5.16K | ﹤0.01% | 5176 |
|
|
2023
Q3 | $179K | Buy |
107,795
+57,601
| +115% | +$103K | ﹤0.01% | 5067 |
|
|
2023
Q2 | $100K | Buy |
+50,194
| New | +$120K | ﹤0.01% | 5355 |
|
|
2018
Q3 | – | Sell |
-2,845
| Closed | -$12K | – | 5746 |
|
|
2018
Q2 | $12K | Buy |
2,845
+1
| +0% | +$4 | ﹤0.01% | 5532 |
|
|
2018
Q1 | $15K | Sell |
2,844
-1
| -0% | -$7 | ﹤0.01% | 5708 |
|
|
2017
Q4 | $19K | Buy |
2,845
+1
| +0% | +$7 | ﹤0.01% | 6121 |
|
|
2017
Q3 | $16K | Buy |
+2,844
| New | +$18.2K | ﹤0.01% | 6458 |
|
|
2017
Q1 | – | Sell |
-4,062
| Closed | -$18K | – | 6950 |
|
|
2016
Q4 | $18K | Buy |
4,062
+8
| +0.2% | +$36 | ﹤0.01% | 6670 |
|
|
2016
Q3 | $23K | Hold |
4,054
| – | – | ﹤0.01% | 6714 |
|
|
2016
Q2 | $26K | Hold |
4,054
| – | – | ﹤0.01% | 6632 |
|
|
2016
Q1 | $34K | Sell |
4,054
-3,643
| -47% | -$31.2K | ﹤0.01% | 6582 |
|
|
2015
Q4 | $79K | Buy |
7,697
+6,432
| +508% | +$65.4K | ﹤0.01% | 6302 |
|
|
2015
Q3 | $15K | Buy |
+1,265
| New | +$20.1K | ﹤0.01% | 7089 |
|
|
2014
Q4 | – | Sell |
-2,835
| Closed | -$69K | – | 7272 |
|
|
2014
Q3 | $69K | Sell |
2,835
-4,099
| -59% | -$118K | ﹤0.01% | 6735 |
|
|
2014
Q2 | $253K | Buy |
6,934
+4,090
| +144% | +$165K | ﹤0.01% | 6014 |
|
|
2014
Q1 | $130K | Sell |
2,844
-30
| -1% | -$1.4K | ﹤0.01% | 6300 |
|
|
2013
Q4 | $112K | Sell |
2,874
-3,172
| -52% | -$134K | ﹤0.01% | 6234 |
|
|
2013
Q3 | $274K | Buy |
6,046
+2,005
| +50% | +$103K | ﹤0.01% | 5632 |
|
|
2013
Q2 | $198K | Buy |
+4,041
| New | +$214K | ﹤0.01% | 5590 |
|
Other funds holding PLX
SWP
Goldman Sachs's PLX Position: Q2 2026 in Review
Goldman Sachs increased its Protalix BioTherapeutics (PLX) stake by 89% in Q2 2026, buying an estimated $476K and bringing the position to 475,922 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #5131.
Goldman Sachs first reported a position in PLX in Q2 2013 and has held it in 29 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.
- Goldman Sachs held 475,922 shares of Protalix BioTherapeutics worth $1.11M as of Q2 2026.
- Goldman Sachs bought 224,577 Protalix BioTherapeutics shares in Q2 2026, an estimated $476K.
- Protalix BioTherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5131 holding.
- Goldman Sachs first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 29 quarters since.
- 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.